|
ZA9811162B
(en)
|
1997-12-12 |
2000-06-07 |
Genentech Inc |
Treatment with anti-ERBB2 antibodies.
|
|
US20040013667A1
(en)
*
|
1999-06-25 |
2004-01-22 |
Genentech, Inc. |
Treatment with anti-ErbB2 antibodies
|
|
US6949245B1
(en)
*
|
1999-06-25 |
2005-09-27 |
Genentech, Inc. |
Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
|
|
US20030086924A1
(en)
*
|
1999-06-25 |
2003-05-08 |
Genentech, Inc. |
Treatment with anti-ErbB2 antibodies
|
|
CA2512729C
(en)
*
|
2003-01-09 |
2014-09-16 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant fc regions and methods of using same
|
|
US7960512B2
(en)
*
|
2003-01-09 |
2011-06-14 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
|
GT200500155A
(es)
*
|
2004-06-16 |
2006-05-15 |
|
Terapia del càncer resistente al platino
|
|
EP1771482B1
(en)
|
2004-07-22 |
2014-08-20 |
Genentech, Inc. |
Her2 antibody composition
|
|
JO3000B1
(ar)
*
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
|
JP2008523073A
(ja)
*
|
2004-12-07 |
2008-07-03 |
ジェネンテック・インコーポレーテッド |
Ｈｅｒ阻害剤を用いた治療のための患者の選択
|
|
EP2028193B1
(en)
|
2005-01-05 |
2012-03-07 |
f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. |
Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
|
|
KR20190016616A
(ko)
*
|
2005-01-21 |
2019-02-18 |
제넨테크, 인크. |
Ｈｅｒ 항체의 고정 용량 투여법
|
|
BRPI0606542A8
(pt)
*
|
2005-02-23 |
2018-03-20 |
Genentech Inc |
métodos para aumentar o tempo de progressão de uma doença (ttp)
|
|
BRPI0607235A2
(pt)
|
2005-02-24 |
2009-08-25 |
Amgen Inc |
mutações do receptor do fator de crescimento epidérmico
|
|
PE20070207A1
(es)
|
2005-07-22 |
2007-03-09 |
Genentech Inc |
Tratamiento combinado de los tumores que expresan el her
|
|
PT1919503E
(pt)
*
|
2005-08-10 |
2015-01-05 |
Macrogenics Inc |
Identificação e manipulação de anticorpos com a regiões de fc variantes e métodos de utilização dos mesmos
|
|
US8084027B2
(en)
*
|
2006-02-10 |
2011-12-27 |
Nerviano Medical Sciences S.R.L. |
Combinations comprising a CDK inhibitor and a growth factor antibody or anti-mitotic
|
|
CA2644903A1
(en)
*
|
2006-03-10 |
2007-09-20 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant heavy chains and methods of using same
|
|
US7786270B2
(en)
|
2006-05-26 |
2010-08-31 |
Macrogenics, Inc. |
Humanized FcγRIIB-specific antibodies and methods of use thereof
|
|
EP2032159B1
(en)
|
2006-06-26 |
2015-01-07 |
MacroGenics, Inc. |
Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof
|
|
SI2029173T1
(sl)
|
2006-06-26 |
2016-12-30 |
Macrogenics, Inc. |
Protitelesa, specifična za Fc RIIB, in postopki za njihovo uporabo
|
|
AT503889B1
(de)
|
2006-07-05 |
2011-12-15 |
Star Biotechnologische Forschungs Und Entwicklungsges M B H F |
Multivalente immunglobuline
|
|
EP1878747A1
(en)
|
2006-07-11 |
2008-01-16 |
greenovation Biotech GmbH |
Glyco-engineered antibodies
|
|
WO2008073160A2
(en)
*
|
2006-08-17 |
2008-06-19 |
The Trustees Of Columbia University In The City Of New York |
Methods for converting or inducing protective immunity
|
|
US20080112961A1
(en)
*
|
2006-10-09 |
2008-05-15 |
Macrogenics, Inc. |
Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using Same
|
|
WO2008140603A2
(en)
|
2006-12-08 |
2008-11-20 |
Macrogenics, Inc. |
METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING
|
|
CN103432580A
(zh)
|
2007-03-02 |
2013-12-11 |
健泰科生物技术公司 |
基于低her3表达预测对her二聚化抑制剂的响应
|
|
US7960139B2
(en)
|
2007-03-23 |
2011-06-14 |
Academia Sinica |
Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
|
|
CN101802006B
(zh)
|
2007-06-26 |
2013-08-14 |
F-星生物技术研究与开发有限公司 |
展示结合剂
|
|
JP2010534219A
(ja)
*
|
2007-07-24 |
2010-11-04 |
ノバルティス アーゲー |
Ｅｇｆｒ依存性疾患またはｅｇｆｒファミリーメンバーを標的とする薬剤に対して耐性を獲得した疾患の処置のための、イミダゾキノリンの使用
|
|
RU2370280C2
(ru)
*
|
2007-10-08 |
2009-10-20 |
Институт физико-химической биологии им. А.Н.Белозерского |
СПОСОБ СУПЕРПРОДУКЦИИ В РАСТЕНИИ АНТИТЕЛ ПРОТИВ ОНКОГЕНА HER2/neu
|
|
TWI472339B
(zh)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
|
|
ES2587937T3
(es)
*
|
2008-04-02 |
2016-10-27 |
Macrogenics, Inc. |
Anticuerpos específicos para HER2/neu y métodos para utilizar los mismos
|
|
ES2589912T3
(es)
|
2008-04-02 |
2016-11-17 |
Macrogenics, Inc. |
Anticuerpos específicos para el complejo BCR y procedimientos de uso de los mismos
|
|
EP2113255A1
(en)
|
2008-05-02 |
2009-11-04 |
f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. |
Cytotoxic immunoglobulin
|
|
JP2010006705A
(ja)
*
|
2008-06-13 |
2010-01-14 |
Atlas Antibodies Ab |
Ｈｅｒ２サブセット
|
|
BRPI0812682A2
(pt)
|
2008-06-16 |
2010-06-22 |
Genentech Inc |
tratamento de cáncer de mama metastático
|
|
JP5986745B2
(ja)
|
2008-07-15 |
2016-09-06 |
アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ |
Ｐｔｆｅ様のアルミニウム・コート・ガラススライド上のグリカンアレイおよび関連する方法
|
|
EP2362783A2
(en)
|
2008-10-31 |
2011-09-07 |
Biogen Idec MA Inc. |
Light targeting molecules and uses thereof
|
|
EP2401378B1
(en)
*
|
2009-02-25 |
2013-08-14 |
Merck Sharp & Dohme Corp. |
Metabolic engineering of a galactose assimilation pathway in the glycoengineered yeast pichia pastoris
|
|
EP2400984A4
(en)
*
|
2009-02-25 |
2013-01-23 |
Merck Sharp & Dohme |
HER2 ANTIBODY COMPOSITIONS
|
|
US8401035B2
(en)
*
|
2009-07-14 |
2013-03-19 |
Level 3 Communications, Llc |
One way SRS information transmission method
|
|
US8064431B2
(en)
*
|
2009-07-14 |
2011-11-22 |
Level 3 Communications, Llc |
One way information transmission method
|
|
US9345661B2
(en)
*
|
2009-07-31 |
2016-05-24 |
Genentech, Inc. |
Subcutaneous anti-HER2 antibody formulations and uses thereof
|
|
AR078161A1
(es)
|
2009-09-11 |
2011-10-19 |
Hoffmann La Roche |
Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
|
|
US11377485B2
(en)
|
2009-12-02 |
2022-07-05 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
|
US10087236B2
(en)
|
2009-12-02 |
2018-10-02 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
|
JP6184695B2
(ja)
|
2009-12-04 |
2017-08-23 |
ジェネンテック， インコーポレイテッド |
多重特異性抗体、抗体アナログ、組成物、及び方法
|
|
US8937159B2
(en)
*
|
2009-12-16 |
2015-01-20 |
Abbvie Biotherapeutics Inc. |
Anti-HER2 antibodies and their uses
|
|
PH12012501751A1
(en)
|
2010-03-04 |
2012-11-12 |
Macrogenics Inc |
Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
|
|
MA34062B1
(fr)
|
2010-03-04 |
2013-03-05 |
Macrogenics Inc |
Anticorps réagissant avec b7-h3, fragments immunologiquement actifs associés et utilisations associées
|
|
RU2425840C1
(ru)
*
|
2010-04-09 |
2011-08-10 |
Федеральное государственное унитарное предприятие "Государственный научный центр "Научно-исследовательский институт органических полупродуктов и красителей" (ФГУП "ГНЦ "НИОПИК") |
АНТИТЕЛО, СПЕЦИФИЧЕСКИ ВЗАИМОДЕЙСТВУЮЩЕЕ С ОНКОБЕЛКОМ HER2/neu
|
|
US10338069B2
(en)
|
2010-04-12 |
2019-07-02 |
Academia Sinica |
Glycan arrays for high throughput screening of viruses
|
|
WO2011130580A1
(en)
|
2010-04-15 |
2011-10-20 |
Alper Biotech, Llc |
Monoclonal antibodies against her2 antigens, and uses therefor
|
|
WO2011143262A2
(en)
|
2010-05-10 |
2011-11-17 |
Sinica, Academia |
Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses
|
|
EP3539988A3
(en)
|
2010-05-27 |
2019-12-04 |
Genmab A/S |
Monoclonal antibodies against her2
|
|
EP2575880B1
(en)
|
2010-05-27 |
2019-01-16 |
Genmab A/S |
Monoclonal antibodies against her2 epitope
|
|
TW201302793A
(zh)
|
2010-09-03 |
2013-01-16 |
Glaxo Group Ltd |
新穎之抗原結合蛋白
|
|
PL2635604T3
(pl)
|
2010-11-01 |
2017-09-29 |
Symphogen A/S |
Kompozycja przeciwciała PAN-HER
|
|
WO2012125724A1
(en)
|
2011-03-14 |
2012-09-20 |
Beth Israel Deaconess Medical Center |
Methods and compositions for the treatment of proliferative disorders
|
|
CA2832389A1
(en)
|
2011-04-20 |
2012-10-26 |
Genmab A/S |
Bispecific antibodies against her2 and cd3
|
|
CA2843158A1
(en)
|
2011-08-26 |
2013-03-07 |
Merrimack Pharmaceuticals, Inc. |
Tandem fc bispecific antibodies
|
|
JP2014530235A
(ja)
|
2011-10-14 |
2014-11-17 |
ジェネンテック， インコーポレイテッド |
Ｈｅｒ２二量体化阻害剤ペルツズマブの使用及びペルツズマブを含む製造品
|
|
EP2788500A1
(en)
|
2011-12-09 |
2014-10-15 |
F.Hoffmann-La Roche Ag |
Identification of non-responders to her2 inhibitors
|
|
RU2627185C1
(ru)
*
|
2012-03-16 |
2017-08-03 |
Коваген Аг |
Новые связывающие молекулы с противоопухолевой активностью
|
|
US10130714B2
(en)
|
2012-04-14 |
2018-11-20 |
Academia Sinica |
Enhanced anti-influenza agents conjugated with anti-inflammatory activity
|
|
DK2668208T3
(en)
|
2012-04-17 |
2015-08-31 |
Arsanis Biosciences Gmbh |
The cross-reactive antibody Staphylococcus Aureus
|
|
ES2431914B2
(es)
*
|
2012-04-27 |
2014-07-24 |
Universidad De Cádiz |
Anticuerpo monoclonal humano ANTI-HER2
|
|
CA2869529A1
(en)
*
|
2012-05-24 |
2013-11-28 |
Raffaella CASTOLDI |
Multispecific antibodies
|
|
US9730941B2
(en)
|
2012-06-07 |
2017-08-15 |
Beth Israel Deaconess Medical Center, Inc. |
Methods and compositions for the inhibition of Pin1
|
|
SI2859017T1
(sl)
|
2012-06-08 |
2019-05-31 |
Sutro Biopharma, Inc. |
Protitelesa, ki vsebujejo specifične nenaravne aminokislinske ostanke, postopki njihove priprave in postopki njihove uporabe
|
|
EP3135690A1
(en)
|
2012-06-26 |
2017-03-01 |
Sutro Biopharma, Inc. |
Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
|
|
WO2014015137A2
(en)
*
|
2012-07-18 |
2014-01-23 |
Angion Biomedica Corp. |
Compositions and methods for treating dysproliferative diseases
|
|
RU2666990C2
(ru)
|
2012-08-13 |
2018-09-13 |
Дженентек, Инк. |
Антитела к jagged и способы их применения
|
|
WO2014031498A1
(en)
|
2012-08-18 |
2014-02-27 |
Academia Sinica |
Cell-permeable probes for identification and imaging of sialidases
|
|
WO2014031762A1
(en)
|
2012-08-21 |
2014-02-27 |
Academia Sinica |
Benzocyclooctyne compounds and uses thereof
|
|
PL2766048T3
(pl)
|
2012-10-12 |
2015-05-29 |
Medimmune Ltd |
Pirolobenzodiazepiny i ich koniugaty
|
|
AU2013337926B2
(en)
|
2012-10-30 |
2017-12-21 |
Esperance Pharmaceuticals, Inc. |
Antibody/drug conjugates and methods of use
|
|
EP2738180A1
(en)
*
|
2012-11-30 |
2014-06-04 |
Molecular Partners AG |
Binding proteins comprising at least two binding domains against HER2.
|
|
JP6998646B2
(ja)
|
2012-11-30 |
2022-02-04 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
Ｐｄ－ｌ１阻害剤併用療法を必要とする患者の同定
|
|
WO2014093894A2
(en)
|
2012-12-13 |
2014-06-19 |
The Trustees Of The University Of Pennsylvania |
Dna antibody constructs and method of using same
|
|
US9487587B2
(en)
|
2013-03-05 |
2016-11-08 |
Macrogenics, Inc. |
Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
|
|
MX2015011712A
(es)
|
2013-03-06 |
2016-04-04 |
Merrimack Pharmaceuticals Inc |
Anticerpos biespecificos fc en fila anti-c-met.
|
|
US20160031887A1
(en)
|
2013-03-13 |
2016-02-04 |
Medimmune Limited |
Pyrrolobenzodiazepines and conjugates thereof
|
|
RU2015147696A
(ru)
|
2013-04-09 |
2017-05-12 |
Бостон Байомедикал, Инк. |
Способы лечения злокачественной опухоли
|
|
AR095863A1
(es)
|
2013-04-16 |
2015-11-18 |
Genentech Inc |
Variantes de pertuzumab, su evaluación, método de tratamiento, método de preparación y artículo de fabricación
|
|
EP2994164B1
(en)
|
2013-05-08 |
2020-08-05 |
Zymeworks Inc. |
Bispecific her2 and her3 antigen binding constructs
|
|
KR101453462B1
(ko)
*
|
2013-05-16 |
2014-10-23 |
앱클론(주) |
Her2에 특이적으로 결합하는 항체
|
|
WO2014210397A1
(en)
|
2013-06-26 |
2014-12-31 |
Academia Sinica |
Rm2 antigens and use thereof
|
|
WO2014210564A1
(en)
|
2013-06-27 |
2014-12-31 |
Academia Sinica |
Glycan conjugates and use thereof
|
|
CA2923579C
(en)
|
2013-09-06 |
2023-09-05 |
Academia Sinica |
Human inkt cell activation using glycolipids with altered glycosyl groups
|
|
WO2015073721A1
(en)
|
2013-11-13 |
2015-05-21 |
Zymeworks Inc. |
Monovalent antigen binding constructs targeting egfr and/or her2 and uses thereof
|
|
ES2879799T3
(es)
|
2013-11-19 |
2021-11-23 |
Remegen Co Ltd |
Anticuerpo anti-HER2 y conjugado del mismo
|
|
JP6817064B2
(ja)
|
2013-11-27 |
2021-01-20 |
ザイムワークス，インコーポレイテッド |
Ｈｅｒ２を標的とする二重特異性抗原結合性コンストラクト
|
|
CN112062853B
(zh)
|
2013-12-20 |
2024-01-09 |
豪夫迈·罗氏有限公司 |
双特异性her2抗体及使用方法
|
|
HUE042512T2
(hu)
|
2013-12-25 |
2019-07-29 |
Daiichi Sankyo Co Ltd |
Anti-trop2 antitest-gyógyszer konjugátum
|
|
WO2015109180A2
(en)
|
2014-01-16 |
2015-07-23 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
|
US10150818B2
(en)
|
2014-01-16 |
2018-12-11 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
|
PT4212552T
(pt)
*
|
2014-01-31 |
2025-01-20 |
Daiichi Sankyo Co Ltd |
Conjugado anticorpo-fármaco anti-her2
|
|
US20170002046A1
(en)
|
2014-03-11 |
2017-01-05 |
Molecular Templates, Inc. |
Proteins comprising binding regions, shiga toxin a subunit effector regions, and carboxy-terminal, endoplasmic reticulum localization signal motifs
|
|
SMT202100379T1
(it)
|
2014-03-11 |
2021-09-14 |
Molecular Templates Inc |
Proteine comprendenti regioni di effettori di subunita' a di tossina shiga prossimale ammino-terminale e regioni leganti di tipo immunoglobulinico indirizzate a cellule capaci di legare specificamente cd38
|
|
WO2015143271A1
(en)
*
|
2014-03-21 |
2015-09-24 |
X-Body, Inc. |
Bi-specific antigen-binding polypeptides
|
|
JP6562942B2
(ja)
|
2014-03-27 |
2019-08-28 |
アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ |
反応性標識化合物およびその使用
|
|
ES2754348T3
(es)
|
2014-04-10 |
2020-04-17 |
Daiichi Sankyo Co Ltd |
Conjugado de (anticuerpo anti-HER2)-fármaco
|
|
EP3134115A4
(en)
|
2014-04-25 |
2017-10-25 |
The Trustees Of The University Of Pennsylvania |
Methods and compositions for treating metastatic breast cancer and other cancers in the brain
|
|
BR112016024789A2
(pt)
|
2014-04-25 |
2017-10-24 |
Genentech Inc |
métodos de tratamento de câncer de mama em fase inicial com trastuzumabe-mcc-dm1 e pertuzumabe
|
|
CN106573971A
(zh)
|
2014-05-27 |
2017-04-19 |
中央研究院 |
抗cd20醣抗体及其用途
|
|
US10118969B2
(en)
|
2014-05-27 |
2018-11-06 |
Academia Sinica |
Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
|
|
JP6894239B2
(ja)
|
2014-05-27 |
2021-06-30 |
アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ |
増強された抗体の有効性のための普遍的グリコフォームに関する組成物および方法
|
|
TWI679020B
(zh)
|
2014-05-27 |
2019-12-11 |
中央研究院 |
抗ｈｅｒ２醣抗體及其用途
|
|
KR102494193B1
(ko)
|
2014-05-28 |
2023-01-31 |
아카데미아 시니카 |
항-ｔｎｆ-알파 글리코항체 및 이의 용도
|
|
WO2016011265A2
(en)
|
2014-07-17 |
2016-01-21 |
Beth Israel Deaconess Medical Center, Inc. |
Biomarkers for pin1-associated disorders
|
|
US9968579B2
(en)
|
2014-07-17 |
2018-05-15 |
Beth Isreal Deaconess Medical Center, Inc. |
ATRA for modulating Pin1 activity and stability
|
|
KR101608301B1
(ko)
|
2014-08-22 |
2016-04-12 |
앱클론(주) |
Her2에 특이적으로 결합하는 항체
|
|
KR102422375B1
(ko)
|
2014-09-08 |
2022-07-18 |
아카데미아 시니카 |
당지질을 사용한 인간 iNKT 세포 활성화
|
|
WO2016037644A1
(en)
|
2014-09-10 |
2016-03-17 |
Medimmune Limited |
Pyrrolobenzodiazepines and conjugates thereof
|
|
WO2016040723A1
(en)
|
2014-09-12 |
2016-03-17 |
Genentech, Inc. |
Anti-her2 antibodies and immunoconjugates
|
|
CN107124870A
(zh)
|
2014-09-17 |
2017-09-01 |
基因泰克公司 |
包含抗her2抗体和吡咯并苯并二氮杂*的免疫缀合物
|
|
CN104225594B
(zh)
*
|
2014-09-23 |
2016-03-23 |
合肥瀚科迈博生物技术有限公司 |
抗her2人源化抗体及其相关的抗肿瘤组合物
|
|
DK3223848T3
(da)
|
2014-11-27 |
2025-03-03 |
Zymeworks Bc Inc |
Fremgangsmåder til anvendelse af bispecifikke antigenbindingskonstrukter målrettet her2
|
|
MX2017007187A
(es)
|
2014-12-01 |
2018-01-30 |
Univ Pennsylvania |
Construcciones de anticuerpos de adn y metodo para utilizarlas.
|
|
US10495645B2
(en)
|
2015-01-16 |
2019-12-03 |
Academia Sinica |
Cancer markers and methods of use thereof
|
|
US9975965B2
(en)
|
2015-01-16 |
2018-05-22 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
|
TWI736523B
(zh)
|
2015-01-24 |
2021-08-21 |
中央研究院 |
新穎聚醣結合物及其使用方法
|
|
CN105985435B
(zh)
*
|
2015-01-30 |
2019-10-15 |
嘉和生物药业有限公司 |
全人源her2抗体的突变抗体及其编码基因和应用
|
|
US10548864B2
(en)
|
2015-03-12 |
2020-02-04 |
Beth Israel Deaconess Medical Center, Inc. |
Enhanced ATRA-related compounds for the treatment of proliferative diseases, autoimmune diseases, and addiction conditions
|
|
US20180100026A1
(en)
*
|
2015-04-15 |
2018-04-12 |
California Institute For Biomedical Research |
Optimized chimeric receptor t cell switches and uses thereof
|
|
CA2984458A1
(en)
|
2015-05-13 |
2016-11-17 |
Zymeworks Inc. |
Antigen-binding constructs targeting her2
|
|
DK3302551T3
(da)
|
2015-05-30 |
2024-08-26 |
Hoffmann La Roche |
Fremgangsmåder til behandling af HER2-positiv tidligere ubehandlet metastatisk brystkræft
|
|
CN114656573B
(zh)
|
2015-05-30 |
2024-09-27 |
分子模板公司 |
去免疫化的志贺毒素a亚基支架和包含它们的细胞靶向分子
|
|
MX2017015618A
(es)
|
2015-06-03 |
2018-08-15 |
Boston Biomedical Inc |
Composiciones que comprenden un inhibidor de la autorrenovación y diferenciación de células madre cancerosas y un agente inmunoterapéutico para su uso en el tratamiento del cáncer.
|
|
HUE061408T2
(hu)
|
2015-06-29 |
2023-06-28 |
Daiichi Sankyo Co Ltd |
Eljárás antitest-gyógyszer konjugátum szelektív elõállítására
|
|
AU2016297920A1
(en)
|
2015-07-26 |
2018-01-18 |
Molecular Templates, Inc. |
Cell-targeting molecules comprising shiga toxin A subunit effectors and CD8+ T-cell epitopes
|
|
CN105132357B
(zh)
*
|
2015-07-29 |
2019-12-06 |
苏州诺普再生医学有限公司 |
一种用于表皮细胞培养的无血清培养体系
|
|
IL319047A
(en)
|
2015-08-28 |
2025-04-01 |
Amunix Operating Inc |
Chimeric polypeptide composition and methods for its preparation and use
|
|
MA44334A
(fr)
|
2015-10-29 |
2018-09-05 |
Novartis Ag |
Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
|
|
EP4074731A1
(en)
|
2015-11-04 |
2022-10-19 |
City of Hope |
Chimeric antigen receptors targeting her2
|
|
WO2017087280A1
(en)
|
2015-11-16 |
2017-05-26 |
Genentech, Inc. |
Methods of treating her2-positive cancer
|
|
US10689458B2
(en)
|
2015-11-30 |
2020-06-23 |
Pfizer Inc. |
Site specific HER2 antibody drug conjugates
|
|
TW201808978A
(zh)
|
2016-03-08 |
2018-03-16 |
中央研究院 |
N-聚醣及其陣列之模組化合成方法
|
|
RU2648161C2
(ru)
*
|
2016-04-01 |
2018-03-22 |
Юрий Леонидович Дорохов |
Способ получения антитела, специфически связывающего домен димеризации экзоклеточной части онкобелка HER2/neu, в растении, антитело, полученное этим способом, и его применение
|
|
WO2017180813A1
(en)
|
2016-04-15 |
2017-10-19 |
Macrogenics, Inc. |
Novel b7-h3 binding molecules, antibody drug conjugates thereof and methods of use thereof
|
|
KR101923624B1
(ko)
|
2016-07-28 |
2018-11-30 |
고려대학교 산학협력단 |
암세포 화학요법을 위한 agtr1 압타머-항암약물 복합체
|
|
AU2017316663B2
(en)
|
2016-08-22 |
2024-02-22 |
CHO Pharma Inc. |
Antibodies, binding fragments, and methods of use
|
|
EP3525829A1
(en)
|
2016-10-11 |
2019-08-21 |
Medimmune Limited |
Antibody-drug conjugates with immune-mediated therapy agents
|
|
CN110505880A
(zh)
|
2016-11-04 |
2019-11-26 |
基因泰克公司 |
Her2阳性乳腺癌的治疗
|
|
KR101923641B1
(ko)
|
2016-11-25 |
2018-11-29 |
재단법인 목암생명과학연구소 |
항her3 항체 및 이를 포함하는 암 예방 또는 치료용 조성물
|
|
CA3045306A1
(en)
|
2016-11-29 |
2018-06-07 |
Boston Biomedical, Inc. |
Naphthofuran derivatives, preparation, and methods of use thereof
|
|
CA3046293A1
(en)
|
2016-12-12 |
2018-06-21 |
Daiichi Sankyo Company, Limited |
Combination of antibody-drug conjugate and immune checkpoint inhibitor
|
|
EP3562844A1
(en)
|
2016-12-28 |
2019-11-06 |
Genentech, Inc. |
Treatment of advanced her2 expressing cancer
|
|
CN110382535A
(zh)
|
2017-01-17 |
2019-10-25 |
第一三共株式会社 |
抗-gpr20抗体以及抗-gpr20抗体-药物缀合物
|
|
HUE052551T2
(hu)
*
|
2017-01-17 |
2021-05-28 |
Genentech Inc |
Szubkután HER2 antitest készítmények
|
|
CN110312736B
(zh)
|
2017-01-23 |
2023-05-09 |
苏州康宁杰瑞生物科技有限公司 |
Pd-l1结合多肽或化合物
|
|
CA3049456A1
(en)
|
2017-01-25 |
2018-08-02 |
Molecular Templates, Inc. |
Cell-targeting molecules comprising de-immunized, shiga toxin a subunit effectors and cd8+ t-cell epitopes
|
|
MX2019009468A
(es)
|
2017-02-08 |
2020-01-20 |
Dragonfly Therapeutics Inc |
Proteínas de unión multiespecíficas para la activación de células asesinas naturales y usos terapéuticos de las mismas para tratar cáncer.
|
|
DK3582806T5
(da)
*
|
2017-02-20 |
2024-09-02 |
Dragonfly Therapeutics Inc |
Proteiner, der binder her2, nkg2d og cd16
|
|
WO2018160654A2
(en)
|
2017-03-02 |
2018-09-07 |
Genentech, Inc. |
Adjuvant treatment of her2-positive breast cancer
|
|
EP3617221A4
(en)
|
2017-04-19 |
2021-04-14 |
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. |
CYTOTOXIN AND CONJUGATE, USES THEREOF AND MANUFACTURING PROCESSES THEREFORE
|
|
KR20190140952A
(ko)
|
2017-04-24 |
2019-12-20 |
제넨테크, 인크. |
막관통 및 인접막 도메인에서의 erbb2/her2 돌연변이
|
|
AR111651A1
(es)
|
2017-04-28 |
2019-08-07 |
Novartis Ag |
Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
|
|
TW202504643A
(zh)
|
2017-05-15 |
2025-02-01 |
日商第一三共股份有限公司 |
抗體－藥物結合物之用途
|
|
US10646464B2
(en)
|
2017-05-17 |
2020-05-12 |
Boston Biomedical, Inc. |
Methods for treating cancer
|
|
SG11202000997YA
(en)
|
2017-08-31 |
2020-03-30 |
Daiichi Sankyo Co Ltd |
Improved method for producing antibody-drug conjugate
|
|
BR112020003466B1
(pt)
|
2017-08-31 |
2023-12-12 |
Daiichi Sankyo Company, Limited |
Métodos de produção de composto, e, composto
|
|
CN111132998B
(zh)
|
2017-09-25 |
2024-01-30 |
苏州丁孚靶点生物技术有限公司 |
用于癌症治疗的方法和组合物
|
|
JP7386796B2
(ja)
*
|
2017-11-14 |
2023-11-27 |
グリーン クロス ラボ セル コーポレーション |
抗－ｈｅｒ２抗体又はその抗原結合フラグメント、及びこれを含むキメラ抗原受容体
|
|
US11649294B2
(en)
|
2017-11-14 |
2023-05-16 |
GC Cell Corporation |
Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
|
|
CN111295389B
(zh)
|
2017-12-15 |
2021-10-22 |
四川科伦博泰生物医药股份有限公司 |
生物活性物偶联物及其制备方法和用途
|
|
BR112020016190A2
(pt)
|
2018-02-08 |
2020-12-15 |
Dragonfly Therapeutics, Inc. |
Domínios variáveis de anticorpos direcionando o receptor nkg2d
|
|
SG11202007945UA
(en)
|
2018-02-20 |
2020-09-29 |
Dragonfly Therapeutics Inc |
Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use
|
|
TWI841551B
(zh)
|
2018-03-13 |
2024-05-11 |
瑞士商赫孚孟拉羅股份公司 |
使用靶向4-1bb (cd137)之促效劑的組合療法
|
|
EP3773676A4
(en)
*
|
2018-04-03 |
2022-05-18 |
Dragonfly Therapeutics, Inc. |
Proteins binding nkg2d, cd16 and an antigen associated with tumors, mdscs and/or tams
|
|
JP7418346B2
(ja)
|
2018-04-13 |
2024-01-19 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
４－１ＢＢＬを含むＨｅｒ２標的化抗原結合分子
|
|
CA3097178A1
(en)
|
2018-04-17 |
2019-10-24 |
Molecular Templates, Inc. |
Her2-targeting molecules comprising de-immunized, shiga toxin a subunit scaffolds
|
|
US20210187118A1
(en)
|
2018-05-18 |
2021-06-24 |
Daiichi Sankyo Co., Ltd. |
Anti-muc1 antibody-drug conjugate
|
|
CN113286616A
(zh)
|
2018-05-23 |
2021-08-20 |
Adc治疗有限公司 |
分子佐剂
|
|
WO2019232323A1
(en)
*
|
2018-05-31 |
2019-12-05 |
Board Of Regents, The University Of Texas System |
Bi-specific antibodies and use thereof
|
|
TW202415410A
(zh)
|
2018-07-31 |
2024-04-16 |
日商第一三共股份有限公司 |
抗體-藥物結合物之用途
|
|
CN112955463B
(zh)
|
2018-08-01 |
2024-07-05 |
赛福伦有限责任公司 |
抗cxcr2抗体及其用途
|
|
EA202091888A1
(ru)
|
2018-08-08 |
2020-10-23 |
Драгонфлай Терапьютикс, Инк. |
Вариабельные домены антител, нацеленные на рецептор nkg2d
|
|
UA129187C2
(uk)
|
2018-10-15 |
2025-02-05 |
Дженентек, Інк. |
Спосіб лікування залишкового раку молочної залози трастузумабом емтанзином
|
|
WO2020084503A1
(en)
|
2018-10-26 |
2020-04-30 |
Cadila Healthcare Limited |
A composition comprising antibody with reduced level of basic variants thereof
|
|
JP7301155B2
(ja)
|
2019-04-12 |
2023-06-30 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
リポカリンムテインを含む二重特異性抗原結合分子
|
|
CA3159770A1
(en)
|
2019-11-15 |
2021-05-20 |
Seagen Inc. |
Methods of treating her2 positive breast cancer with tucatinib in combination with an anti-her2 antibody-drug conjugate
|
|
US12076400B2
(en)
|
2019-12-06 |
2024-09-03 |
Zymeworks Bc Inc. |
Methods of using a bispecific antigen-binding construct targeting HER2 in combination with CDK4/6 inhibitors for the treatment of breast cancer
|
|
TW202200619A
(zh)
*
|
2020-03-17 |
2022-01-01 |
美商西雅圖免疫公司 |
引導及導航控制(gnc)抗體樣蛋白質及製造與使用其之方法
|
|
IL297922A
(en)
|
2020-05-06 |
2023-01-01 |
Dragonfly Therapeutics Inc |
Proteins binding nkg2d, cd16 and clec12a
|
|
CR20220627A
(es)
|
2020-06-23 |
2023-02-17 |
Hoffmann La Roche |
Moléculas agonistas de unión al antígeno cd28 que se derigen a her2
|
|
CN115916834A
(zh)
|
2020-06-29 |
2023-04-04 |
基因泰克公司 |
帕妥珠单抗加曲妥珠单抗的固定剂量组合
|
|
IL299121A
(en)
|
2020-07-14 |
2023-02-01 |
Hoffmann La Roche |
Tests for fixed dose combinations
|
|
WO2022079211A1
(en)
|
2020-10-16 |
2022-04-21 |
Adc Therapeutics Sa |
Glycoconjugates
|
|
AU2022220512A1
(en)
|
2021-02-09 |
2023-07-13 |
Medilink Therapeutics (Suzhou) Co., Ltd. |
Bioactive substance conjugate, preparation method therefor and use thereof
|
|
GB202102396D0
(en)
|
2021-02-19 |
2021-04-07 |
Adc Therapeutics Sa |
Molecular adjuvant
|
|
WO2022242724A1
(zh)
|
2021-05-19 |
2022-11-24 |
上海迪诺医药科技有限公司 |
一种含氮化合物、含其的偶联物及其应用
|
|
WO2023280092A1
(zh)
|
2021-07-05 |
2023-01-12 |
江苏康宁杰瑞生物制药有限公司 |
抗体药物偶联物及其应用
|
|
TW202310878A
(zh)
|
2021-07-22 |
2023-03-16 |
大陸商上海森輝醫藥有限公司 |
艾日布林衍生物的藥物偶聯物
|
|
AU2021362997A1
(en)
|
2021-11-03 |
2024-05-16 |
Hangzhou Dac Biotech Co., Ltd. |
Specific conjugation of an antibody
|
|
CN119300856A
(zh)
*
|
2022-02-19 |
2025-01-10 |
萨尔维图斯公司 |
益生菌疫苗和相关使用方法
|
|
CN117801107A
(zh)
|
2022-09-30 |
2024-04-02 |
上海迪诺医药科技有限公司 |
苯并氮杂卓衍生物、含其的偶联物及其应用
|
|
WO2024173565A2
(en)
*
|
2023-02-14 |
2024-08-22 |
New York University |
Human synthetic antibodies targeting human epidermal growth factor receptor 2 (her2) mutants
|
|
WO2025019254A1
(en)
|
2023-07-14 |
2025-01-23 |
Guardant Health, Inc. |
Classification of breast tumors using dna methylation from liquid biopsy
|